Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses

10-May-2012 - Kentucky Bioprocessing, LLC (KBP), Icon Genetics, GmbH (ICON) and Mapp Biopharmaceutical, Inc. (Mappbio) have announced that they have entered into detailed negotiations aimed at merging the companies to create a single, fully integrated biopharmaceutical discovery, development and manufacturing ...

Pilot plant for future-oriented technology opens in Halle: Bayer will use tobacco plants to produce medicines

First development candidate from the new plant for cancer indication non-Hodgkin's lymphoma

18-Jun-2008 - Medicinal products from plants or even tobacco for health - a vision that could soon become reality. Bayer and its subsidiary Icon Genetics have together developed a new production process that can be used to produce biotech drugs in tobacco plants. A new production facility for therapeutic ...

AmVac AG Begins Research Cooperation with Bayer

Research Laboratory Inaugurated in Catania

16-Jun-2008 - AmVac AG is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the ...

Icon Genetics and Novoplant announce broad license agreement

03-Nov-2003 - Icon Genetics AG, Munich, and Novoplant GmbH, Gatersleben, have announced today that the two companies entered into a broad licensing agreement that gives Novoplant an access to Icon's proprietary technology platforms, Transgene Operating Systems®, for manufacturing immune response proteins in ...